Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIFICO for Postoperative Liver Function Recovery in HCC
NCT05178524Completed
- Sponsor
- Tongji Hospital
- Start
- Jun 2021
- Primary completion
- May 2022
- Modality
- Yeast Strains, Defined Consortia, Bacterial Strains
- Countries
- 1
01
Overview
Randomised, open-label trial of bifidobacterium longum/lactobacillus acidophilus/enterococcus faecalis in hepatocellular carcinoma (HCC) (2 arms), sponsored by Tongji Hospital. Primary endpoints: Liver function recovery (Total bilirubin and Prothrombin activity), Alpha and beta diversity of gut microbiota and 1 more. Started Jun 2021; status: completed.
02
Drugs
bifidobacterium longum/lactobacillus acidophilus/enterococcus faecalis
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05178524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05178524.